IDBS engaged to help Genevant advance drug discoveries

12 March, 2019; ID Business Solutions (IDBS), a leader in enterprise scientific informatics platforms, is pleased to announce a new SaaS contract with Genevant Sciences Corporation, a leading biopharmaceutical company focused on the discovery and development of a broad range of RNA-based therapeutics across multiple modalities. The arrangement will combine Genevant’s RNA therapeutic expertise with the R&D and discovery data management expertise of IDBS. This includes IDBS’ E-WorkBook Electronic Laboratory Notebook (ELN), designed to capture and manage critical data to increase laboratory efficiency and boost compliance by reducing errors and strengthening lab safety.

Christian Marcazzo, General Manager at IDBS said: “We are delighted to win this high-profile contract with one of the first modality-agnostic RNA therapeutics companies. Our work with Genevant will focus on research and development of innovative new medicines and potential cures.  On our cloud platform, Genevant is empowered to solely focus on their science and future therapeutics for improving patient outcomes.”

The E-WorkBook Cloud platform will run on the Amazon Web Services (AWS) Cloud, providing Genevant, including IDBS’ cloud-based ELN, with the tools to improve throughput and the amount of studies it can achieve, ultimately leading to more efficient, productive researchers. With the support and partnership of AWS, The E-WorkBook Cloud puts Genevant in the best position to accelerate its business’ scientific innovation and bring new therapeutics to market for patients.

– Ends –

 

For media enquiries, please contact:

Orsolya Fekete

Metia Group

orsolya.fekete@metia.com

+44 203 100 3564

About IDBS:

IDBS helps research and development (R&D) teams around the world make discoveries that have the potential to transform the lives of populations worldwide.

Our advanced scientific informatics platform, The E-WorkBook Cloud, enables organizations to securely capture, manage, share and gain insight from their structured and unstructured data.

  

Our diverse customer list includes 22 of the top 25 global pharmaceutical companies, and other R&D-driven organizations in biotechnology, agricultural sciences, chemicals, consumer goods, energy, food and beverage, and healthcare.

Privately held since 1989, IDBS joined Danaher's Life Sciences platform at the end of 2017. IDBS will help provide the foundation for a portfolio of life sciences informatics and knowledge management solutions, within Danaher, that will accelerate the speed of discovering, developing and producing new drugs and therapies.

Further information can be found at https://www.idbs.com/, or follow us on Twitter @IDBSsoftware.

Back to news